Pfizer developing new versions of biotech drugs: Report
Citing Pfizer officials, WSJ said the company is in mid-stage development of three large molecules.
Pfizer Inc is developing improved versions of top-selling biotechnology drugs, the Wall Street Journal (WSJ) reported on Tuesday.Citing Pfizer officials, WSJ said the company is in mid-stage development of three large molecules. It said two of them aim to improve on Rituxan, a drug co-marketed by Roche Holding AG and Biogen Idec Inc, while the third aims to reduce how often medicines like Enbrel, which Pfizer co-markets with Amgen Inc, need to be injected.Each of the compounds is years away from coming onto the market, the paper said.Pfizer officials could not immediately be reached for comment.